Cefpodoxime

Revision as of 20:01, 6 January 2015 by Rabin Bista (talk | contribs)
Jump to navigation Jump to search

{{DrugProjectFormSinglePage |authorTag=Rabin Bista, M.B.B.S. [1] |genericName=Cefpodoxime proxetil |aOrAn=a |drugClass=orally administered, extended spectrum, semi-synthetic antibiotic of the cephalosporin class |indicationType=treatment |indication=acute otitis media,pharyngitis,tonsillitis,community-acquired pneumonia,acute bacterial exacerbation of chronic bronchitis,acute uncomplicated urethral and cervical gonorrhea,acute maxillary sinusitis,uncomplicated urinary tract infections and uncomplicated skin and skin structure infections. |hasBlackBoxWarning=Yes |adverseReactions=Diarrhea,Nausea,Vaginal Fungal Infections,Vulvovaginal Infections,Abdominal pain, Headache |blackBoxWarningTitle=ConditionName: |blackBoxWarningBody=BEFORE THERAPY WITH CEFPODOXIME PROXETIL IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS HYPERSENSITIVITY REACTIONS TO CEFPODOXIME, OTHER CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS. IF CEFPODOXIME IS TO BE ADMINISTERED TO PENICILLIN SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSS HYPERSENSITIVITY AMONG BETA-LACTAM ANTIBIOTICS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF PENICILLIN ALLERGY. IF AN ALLERGIC REACTION TO CEFPODOXIME PROXETIL OCCURS, DISCONTINUE THE DRUG. SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINE, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED.


|fdaLIADAdult====Indications===

  • Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilus influenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains).
  • Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes.
  • Community-acquired pneumonia caused by S. pneumoniae or H. Influenzae (including beta-lactamase-producing strains).
  • Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, H. influenzae (non-beta-lactamase-producing strains only), or M. catarrhalis.
  • Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains).
  • Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains).
  • Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains) or Streptococcus pyogenes. Abscesses should be surgically drained as clinically indicated.
  • Acute maxillary sinusitis caused by Haemophilus influenzae (including beta-lactamase-producing strains), Streptococcus pneumoniae, and Moraxella catarrhalis.
  • Uncomplicated urinary tract infections (cystitis) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Staphylococcus saprophyticus.

Dosage

Film Coated Tablets

Granules for oral suspension

Patients with Renal Dysfunction

  • For patients with severe renal impairment (<30 mL/min creatinine clearance), the dosing intervals should be increased to Q 24 hours. In patients maintained on hemodialysis, the dose frequency should be 3 times/week after hemodialysis.
  • When only the serum creatinine level is available, the following formula (based on sex, weight, and age of the patient) may be used to estimate creatinine clearance (mL/min). For this estimate to be valid, the serum creatinine level should represent a steady state of renal function.
  • Males: Weight (kg) x (140 - age)

(mL/min) 72 x serum creatinine (mg/100 mL)

  • Females: 0.85 x above value

(mL/min)

Patients with Cirrhosis

  • Cefpodoxime pharmacokinetics in cirrhotic patients (with or without ascites) are similar to those in healthy subjects. Dose adjustment is not necessary in this population

|offLabelAdultGuideSupport=There is limited information regarding Off-Label Guideline-Supported Use of Cefpodoxime proxetil in adult patients |offLabelAdultNoGuideSupport=There is limited information regarding Off-Label Non–Guideline-Supported Use of Cefpodoxime proxetil in adult patients.


|fdaLIADPed=

|offLabelPedGuideSupport=There is limited information regarding Off-Label Guideline-Supported Use of Cefpodoxime proxetil in pediatric patients.

|offLabelPedNoGuideSupport=There is limited information regarding Off-Label Non–Guideline-Supported Use of Cefpodoxime proxetil in pediatric patients.

|contraindications=Cefpodoxime proxetil is contraindicated in patients with a known allergy to cefpodoxime or to the cephalosporin group of antibiotics. |warnings=* Description

Precautions

  • In patients with transient or persistent reduction in urinary output due to renal insufficiency, the total daily dose of cefpodoxime proxetil should be reduced because high and prolonged serum antibiotic concentrations can occur in such individuals following usual doses. Cefpodoxime, like other cephalosporins, should be administered with caution to patients receiving concurrent treatment with potent diuretics.
  • As with other antibiotics, prolonged use of cefpodoxime proxetil may result in overgrowth of non-susceptible organisms. Repeated evaluation of the patient’s condition is essential. If superinfection occurs during therapy, appropriate measures should be taken.
  • Prescribing cefpodoxime proxetil in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.


|clinicalTrials======Body as a Whole=====

  • Diarrhea
  • Nausea
  • Vaginal Fungal Infections
  • Vulvovaginal Infections
  • Abdominal Pain
  • Headache
Cardiovascular
  • congestive heart failure
  • migraine
  • palpitations
  • vasodilation
  • hematoma
  • hypertension
  • hypotension
Digestive
  • vomiting
  • dyspepsia
  • dry mouth
  • flatulence
  • decreased appetite
  • constipation
  • oral moniliasis
  • anorexia
  • eructation
  • gastritis
  • mouth ulcer
  • gastrointestinal disorders
  • rectal disorders
  • tongue disorders
  • tooth disorders
  • increased thirst
  • oral lesions
  • tenesmus
  • dry throat
  • toothache
Hematologic and Lymphatic
  • anemia
  • Thrombocythemia
  • positive direct Coombs’ test
  • eosinophilia
  • leukocytosis
  • leukopenia
  • prolonged partial thromboplastin time
  • thrombocytopenic purpura
Metabolic and Nutritional
  • dehydration
  • gout
  • peripheral edema
  • weight increase
  • Increased SGPT
Musculoskeletal
  • myalgia
Neurologic
  • dizziness
  • insomnia
  • somnolence
  • anxiety
  • shakiness
  • nervousness
  • cerebral infarction
  • change in dreams
  • impaired concentration
  • confusion
  • nightmares
  • paresthesia
  • vertigo
  • Hallucination
  • hyperkinesia
Respiratory
  • asthma
  • cough
  • epistaxis
  • rhinitis
  • wheezing
  • bronchitis
  • dyspnea
  • pleural effusion
  • pneumonia
  • sinusitis
Skin and Hypersensitivy Reactions
  • urticaria
  • rash
  • pruritus
  • diaphoresis
  • maculopapular rash
  • fungal dermatitis
  • desquamation
  • dry skin non-application site
  • hair loss
  • vesiculobullous rash
  • sunburn
Special Senses
  • taste alterations
  • eye irritation
  • taste loss
  • tinnitus
Urogenital
  • hematuria
  • urinary tract infections
  • metrorrhagia
  • dysuria
  • urinary frequency
  • nocturia
  • penile infection
  • proteinuria
  • vaginal pain
Miscellaneous
  • fungal infections
  • abdominal distention
  • malaise, fatigue
  • asthenia
  • fever
  • chest pain
  • back pain
  • chills
  • generalized pain
  • abnormal microbiological test
  • moniliasis
  • abscess
  • allergic reaction
  • facial edema
  • bacterial infections
  • parasitic infections
  • localized edema
  • localized pain

Laboratory Changes

  • Hepatic: Transient increases in AST (SGOT), ALT (SGPT), GGT, alkaline phosphatase, bilirubin, and LDH.
  • Hematologic: Eosinophilia, leukocytosis, lymphocytosis, granulocytosis, basophilia, monocytosis, thrombocytosis, decreased hemoglobin, decreased hematocrit, leukopenia, neutropenia, lymphocytopenia, thrombocytopenia, thrombocythemia, positive Coombs’ test, and prolonged PT, and PTT.
  • Serum Chemistry: Hyperglycemia, hypoglycemia, hypoalbuminemia, hypoproteinemia, hyperkalemia, and hyponatremia.
  • Renal: Increases in BUN and creatinine.

Cephalosporin Class Labeling

  • In addition to the adverse reactions listed above which have been observed in patients treated with cefpodoxime proxetil, the following adverse reactions and altered laboratory tests have been reported for cephalosporin class antibiotics.
  • Adverse Reactions and Abnormal Laboratory Tests: Renal dysfunction, toxic nephropathy, hepatic dysfunction including cholestasis, aplastic anemia, hemolytic anemia, serum sickness-like reaction, hemorrhage, agranulocytosis, pancytopenia and seizures.

|postmarketing=*The following serious adverse experiences have been reported: allergic reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme and serum sickness-like reactions, pseudomembranous colitis, bloody diarrhea with abdominal pain, ulcerative colitis, rectorrhagia with hypotension, anaphylactic shock, acute liver injury, in utero exposure with miscarriage, purpuric nephritis, pulmonary infiltrate with eosinophilia, and eyelid dermatitis.

  • One death was attributed to pseudomembranous colitis and disseminated intravascular coagulation.

|drugInteractions=*Antacids: Concomitant administration of high doses of antacids (sodium bicarbonate and aluminum hydroxide) or H2 blockers reduces peak plasma levels by 24% to 42% and the extent of absorption by 27% to 32%, respectively. The rate of absorption is not altered by these concomitant medications. Oral anti-cholinergics (e.g., propantheline) delay peak plasma levels (47% increase in Tmax), but do not affect the extent of absorption (AUC).

  • Probenecid: As with other beta-lactam antibiotics, renal excretion of cefpodoxime was inhibited by probenecid and resulted in an approximately 31% increase in AUC and 20% increase in peak cefpodoxime plasma levels.
  • Nephrotoxic drugs: Although nephrotoxicity has not been noted when cefpodoxime proxetil was given alone, close monitoring of renal function is advised when cefpodoxime proxetil is administered concomitantly with compounds of known nephrotoxic potential.

|FDAPregCat=B |useInPregnancyFDA======Pregnancy=====

Teratogenic Effects

Cefpodoxime proxetil was neither teratogenic nor embryocidal when administered to rats during organogenesis at doses up to 100 mg/kg/day (2 times the human dose based on mg/m2) or to rabbits at doses up to 30 mg/kg/day (1 to 2 times the human dose based on mg/m2). There are, however, no adequate and well-controlled studies of cefpodoxime proxetil use in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. |useInPregnancyAUS=There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Cefpodoxime proxetil in women who are pregnant. |useInLaborDelivery=Cefpodoxime proxetil has not been studied for use during labor and delivery. Treatment should only be given if clearly needed |useInNursing=Cefpodoxime is excreted in human milk. In a study of 3 lactating women, levels of cefpodoxime in human milk were 0%, 2% and 6% of concomitant serum levels at 4 hours following a 200 mg oral dose of cefpodoxime proxetil. At 6 hours post-dosing, levels were 0%, 9% and 16% of concomitant serum levels. Because of the potential for serious reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. |useInPed=Safety and efficacy in infants less than 2 months of age have not been established. |useInGeri=Of the 3338 patients in multiple-dose clinical studies of cefpodoxime proxetil film-coated tablets, 521 (16%) were 65 and over, while 214 (6%) were 75 and over. No overall differences in effectiveness or safety were observed between the elderly and younger patients. In healthy geriatric subjects with normal renal function, cefpodoxime half-life in plasma averaged 4.2 hours and urinary recovery averaged 21% after a 400 mg dose was given every 12 hours for 15 days. Other pharmacokinetic parameters were unchanged relative to those observed in healthy younger subjects. Dose adjustment in elderly patients with normal renal function is not necessary. |useInGender=There is no FDA guidance on the use of Cefpodoxime proxetil with respect to specific gender populations. |useInRace=There is no FDA guidance on the use of Cefpodoxime proxetil with respect to specific racial populations. |useInRenalImpair=In patients with transient or persistent reduction in urinary output due to renal insufficiency, the total daily dose of cefpodoxime proxetil should be reduced because high and prolonged serum antibiotic concentrations can occur in such individuals following usual doses. Cefpodoxime, like other cephalosporins, should be administered with caution to patients receiving concurrent treatment with potent diuretics. |useInHepaticImpair=There is no FDA guidance on the use of Cefpodoxime proxetil in patients with hepatic impairment. |useInReproPotential=There is no FDA guidance on the use of Cefpodoxime proxetil in women of reproductive potentials and males. |useInImmunocomp=There is no FDA guidance one the use of Cefpodoxime proxetil in patients who are immunocompromised.

|administration=* Oral Tablets : administer tablets orally with food to enhance absorption

  • Oral Suspension : give without regard to food

|monitoring=There is limited information regarding Monitoring of Cefpodoxime in the drug label.

  • Description

|IVCompat=There is limited information regarding IV Compatibility of Cefpodoxime in the drug label.

|overdose=*In acute rodent toxicity studies, a single 5 g/kg oral dose produced no adverse effects.

  • In the event of serious toxic reaction from overdosage, hemodialysis or peritoneal dialysis may aid in the removal of cefpodoxime from the body, particularly if renal function is compromised.
  • The toxic symptoms following an overdose of beta-lactam antibiotics may include nausea, vomiting, epigastric distress, and diarrhea.

|drugBox=

|mechAction=Cefpodoxime is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Cefpodoxime has activity in the presence of some beta-lactamases, both penicillinases and cephalosporinases, of Gram-negative and Gram-positive bacteria.

|structure=*The chemical name is (RS)-1(isopropoxycarbonyloxy) ethyl (+)-(6R,7R)-7-[2-(2-amino-4-thiazolyl)-2-{(Z)methoxyimino}acetamido]-3-methoxymethyl-8-oxo-5-thia-1-azabicyclo [4.2.0]oct-2-ene- 2-carboxylate.

  • Its molecular formula is C21 H27 N5 O9 S2 and its structural formula is represented below:
File:Cefpodoxime01.png
This image is provided by the National Library of Medicine.

|PD=There is limited information regarding Pharmacodynamics of Cefpodoxime in the drug label.

|PK=There is limited information regarding Pharmacokinetics of Cefpodoxime in the drug label.

|nonClinToxic=There is limited information regarding Nonclinical Toxicology of Cefpodoxime in the drug label.

|clinicalStudies=There is limited information regarding Clinical Studies of Cefpodoxime in the drug label.

|howSupplied=* |packLabel= |fdaPatientInfo=There is limited information regarding Patient Counseling Information of Cefpodoxime in the drug label.

|alcohol=* Alcohol-Cefpodoxime interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

|brandNames=*Vantin |lookAlike=* A® — B®[1]

}} {{#subobject: 

 |Page Name=Cefpodoxime
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage={{{dosageValue}}} {{{dosageUnit}}}
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}

{{#subobject: 

 |Label Page=Cefpodoxime
 |Label Name=Cefpodoxime11.png

}}

{{#subobject: 

 |Label Page=Cefpodoxime
 |Label Name=Cefpodoxime11.png

}}

  1. ↑ "http://www.ismp.org". External link in |title= (help)
Retrieved from "https://www.wikidoc.org/index.php?title=Cefpodoxime&oldid=1052094"